ADENOSINE Drug Patent Profile

When do Adenosine patents expire, and when can generic versions of Adenosine launch?

Adenosine is a drug marketed by Am Regent, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hikma, Mylan Labs Ltd, Pharmobedient, Rising, Teva Pharms Usa, Wockhardt, Avet Lifesciences, Eugia Pharma, Hospira, Meitheal, and Mylan Asi. and is included in twenty-one NDAs.

The generic ingredient in ADENOSINE is adenosine. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adenosine

A generic version of ADENOSINE was approved as adenosine by HIKMA on June 16^th, 2004.

Summary for ADENOSINE

US Patents:	0
Applicants:	15
NDAs:	21
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	135
Clinical Trials:	662
Patent Applications:	6,811
Drug Prices:	Drug price information for ADENOSINE
DailyMed Link:	ADENOSINE at DailyMed

See drug prices for ADENOSINE

Recent Clinical Trials for ADENOSINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nandakumar Narayanan	PHASE1
Assiut University	NA
Vanderbilt University Medical Center	PHASE1

See all ADENOSINE clinical trials

Pharmacology for ADENOSINE

Drug Class	Adenosine Receptor Agonist
Mechanism of Action	Adenosine Receptor Agonists

Medical Subject Heading (MeSH) Categories for ADENOSINE

Analgesics

Anti-Arrhythmia Agents

Purinergic P1 Receptor Agonists

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for ADENOSINE

C01EB	Other cardiac preparations
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ADENOSINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADENOSCAN	Injection	adenosine	3 mg/mL, 20 mL and 30 mL vials	020059	1	2005-04-18

US Patents and Regulatory Information for ADENOSINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	090450-002	Oct 2, 2014	AP	RX	No	No
Am Regent	ADENOSINE	adenosine	INJECTABLE;INJECTION	090010-001	Apr 28, 2009		DISCN	No	No
Eugia Pharma	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	205331-002	Nov 2, 2017	AP	RX	No	No

ADENOSINE MARKET DYNAMICS, PATENT STATUS, AND FINANCIAL TRAJECTORY

Last updated: August 16, 2026

Adenosine is a mature, multisource injectable drug with low unit pricing, limited patent protection, and stable clinical demand. Its principal markets are acute termination of paroxysmal supraventricular tachycardia (PSVT) and pharmacologic stress testing for myocardial perfusion imaging. Financial growth is constrained by generic competition, hospital purchasing pressure, and substitution by regadenoson in cardiac stress testing. The strongest commercial opportunities are in manufacturing efficiency, ready-to-use delivery systems, shortage supply, and geographic markets with expanding diagnostic infrastructure.

What is adenosine used for?

Adenosine is a short-acting purine nucleoside administered intravenously. FDA-approved uses include:

• Conversion of PSVT to sinus rhythm.
• Pharmacologic stress testing when patients cannot exercise adequately.
• Adjunctive use with radionuclide myocardial perfusion imaging.

Adenosine has an extremely short plasma half-life, generally less than 10 seconds, because it is rapidly taken up by cells and metabolized. Its short duration allows rapid onset and termination of pharmacologic effect but requires administration by rapid intravenous bolus or continuous infusion, depending on the indication.[1]

Adenosine clinical applications

Application	Typical clinical role	Commercial implication
PSVT conversion	Acute termination of AV-node-dependent tachycardia	Emergency and hospital demand; low-volume, essential-use product
Myocardial perfusion stress testing	Coronary vasodilation before nuclear imaging	Larger procedural market but subject to regadenoson substitution
Electrophysiology procedures	Diagnostic and therapeutic AV-node testing	Specialized, relatively stable demand
Research and investigational use	Cardiovascular and cellular signaling studies	Small commercial market

Adenosine is not a chronic therapy. Demand is therefore tied to emergency-department encounters, hospital protocols, electrophysiology activity, nuclear cardiology volumes, and stocking practices rather than prescription-refill behavior.

How large is the adenosine market?

Public market estimates for adenosine vary materially because analysts use different definitions. Some include only injectable adenosine used in hospitals. Others include adenosine-related cardiac stress-testing products, combination kits, or broader cardiovascular diagnostic markets. No authoritative public source reports a single global adenosine revenue figure.

The addressable market is best understood as a mature hospital injectable segment rather than a high-growth pharmaceutical category.

Market structure

The commercial market has four characteristics:

1. Generic supply dominates standard adenosine injection.
2. Hospital systems buy through group purchasing organizations and distributors.
3. Revenue is concentrated in relatively few institutional customers.
4. Product differentiation depends more on packaging, supply reliability, and regulatory compliance than on molecular innovation.

Demand is supported by continued use of adenosine in PSVT and by cardiac imaging procedures. Demand is reduced by the adoption of regadenoson, which is easier to administer and generally better tolerated in many stress-testing workflows.

Principal demand drivers

The main volume drivers are:

• Emergency-department treatment of stable, regular narrow-complex PSVT.
• Nuclear myocardial perfusion imaging.
• Electrophysiology laboratory procedures.
• Hospital stocking requirements for emergency cardiovascular drugs.
• Growth in cardiovascular diagnosis in emerging markets.
• Availability of low-cost generic sterile injectables.

Adenosine demand is less sensitive to consumer advertising, outpatient formulary competition, or adherence trends because the drug is administered by healthcare professionals.

Who manufactures adenosine injection?

Adenosine is supplied by multiple generic and specialty-injectable manufacturers. The supplier set changes by country and over time because sterile injectable products are frequently discontinued, acquired, or temporarily unavailable.

In the United States, historical and current suppliers have included manufacturers such as Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Pfizer-related Hospira operations, and other abbreviated new drug application (ANDA) holders. Product availability should be confirmed through the FDA Drugs@FDA database, DailyMed, and current National Drug Code listings rather than relying on historical supplier lists.[2][3]

Product forms and strengths

Common U.S. presentations include:

• 3 mg/mL injection.
• 6 mg/2 mL single-dose syringes or vials.
• 12 mg/4 mL single-dose syringes or vials.
• Larger-volume containers for stress-testing infusion protocols.

Product presentations vary by manufacturer. Hospitals may prefer prefilled syringes because they reduce preparation time and dosing errors in emergency settings. The active pharmaceutical ingredient is generic adenosine; the principal competitive variables are concentration, container closure, syringe format, shelf life, labeling, and supply continuity.

What is the FDA regulatory status of adenosine?

Adenosine injection is an FDA-approved prescription drug and is generally marketed through abbreviated approval pathways or legacy approved applications. The principal regulatory burden is manufacturing sterile injectable product consistently and demonstrating bioequivalence or equivalence where applicable.

FDA-approved labeling identifies adenosine for PSVT conversion and as a pharmacologic stress agent for myocardial perfusion imaging.[1] The drug is administered in controlled clinical settings because it can cause transient atrioventricular block, flushing, chest discomfort, dyspnea, bronchospasm, hypotension, and other acute reactions.

FDA regulatory risks

The principal regulatory risks are manufacturing-related:

• Sterility failures.
• Particulate contamination.
• Container-closure defects.
• Shortages caused by limited sterile-fill capacity.
• Manufacturing-site changes.
• Product recalls.
• Labeling deviations.
• Inadequate supply of raw material or finished-dose inventory.

For a mature injectable, an FDA warning letter, recall, or facility interruption can have a larger commercial effect than a patent event. Hospitals often maintain limited supplier redundancy for low-margin products, which can increase the value of reliable production.

What patents protect adenosine?

Adenosine itself has no meaningful remaining composition-of-matter patent protection in the United States. The molecule is an endogenous nucleoside that has been used clinically for decades. The commercial product is generally exposed to generic competition.

Patent estate by category

Patent category	Current commercial relevance
Adenosine composition patents	No meaningful remaining protection for the basic molecule
PSVT method-of-use patents	Historical protection has expired or is commercially weak
Cardiac stress-testing patents	Relevant claims generally concern formulations, delivery systems, or imaging workflows rather than adenosine itself
Formulation patents	Potentially relevant for proprietary mixtures, stabilized solutions, or devices, but not typical generic adenosine injection
Manufacturing patents	May protect process improvements, but usually do not block standard generic supply
Device patents	May cover prefilled syringes, injectors, or infusion systems rather than adenosine as an active ingredient

The Orange Book should be reviewed for the specific listed drug and dosage form because listings can differ by product and application. The existence of an Orange Book listing does not mean that the basic adenosine molecule remains protected. FDA’s Orange Book identifies approved products, patents, and regulatory exclusivities associated with listed applications.[4]

When does adenosine lose exclusivity?

Adenosine lost practical market exclusivity many years ago. There is no current commercial exclusivity period comparable to that of a recently approved innovative drug.

The relevant timeline is:

Period	Event
1940s-1950s	Adenosine pharmacology and cardiovascular effects established in medical research
1980s-1990s	Clinical use developed for supraventricular tachycardia and cardiac stress testing
1990s	FDA-approved branded and injectable products entered routine hospital practice
2000s onward	Generic competition expanded and pricing declined
Current market	Multisource injectable supply with limited product-level differentiation

Because the core molecule and principal clinical uses are old, a new entrant would not normally face a blocking adenosine patent. Its principal barriers would be FDA approval, sterile manufacturing capacity, quality systems, distribution, and contracting access.

Are there Paragraph IV challenges involving adenosine?

Paragraph IV litigation is unlikely to be commercially material for standard adenosine injection because the relevant product is long genericized and does not depend on a recent innovator patent estate.

An ANDA applicant may make Paragraph IV certifications when an Orange Book-listed patent is asserted against the reference product. In practice, adenosine applicants are more likely to rely on non-infringement, invalidity, or certification pathways associated with old or product-specific listings than to face high-value patent litigation.

The major competitive threat is therefore not a Paragraph IV launch event. It is price competition among approved suppliers and the risk that a manufacturer exits the market.

What formulations are protected by adenosine patents?

Standard aqueous adenosine injection is generally not protected by a commercially significant active-ingredient patent estate. Potentially protectable subject matter includes:

• Stabilized adenosine solutions.
• Concentrated presentations.
• Premixed infusion bags.
• Ready-to-administer syringes.
• Device-assisted rapid bolus delivery.
• Combination products for nuclear imaging.
• Modified-release or tissue-targeted formulations.
• Pharmaceutical compositions designed to reduce degradation or improve storage.

These technologies could support differentiated pricing if they produce a clear operational benefit. The commercial hurdle is high because hospitals often consider adenosine a low-cost commodity unless a new presentation reduces medication errors, preparation time, or waste.

How does adenosine compare with regadenoson?

Regadenoson is the most important commercial substitute in pharmacologic cardiac stress testing. It is a selective A2A adenosine receptor agonist administered as a single intravenous bolus. Adenosine requires weight-based infusion and more complex administration in many stress-testing protocols.[5]

Attribute	Adenosine	Regadenoson
Administration	Continuous infusion for stress testing; rapid bolus for PSVT	Single intravenous bolus for stress testing
Main use	PSVT conversion and cardiac stress testing	Cardiac stress testing
Selectivity	Nonselective adenosine receptor agonist	Relatively selective A2A agonist
Operational burden	Higher for stress testing	Lower
Unit economics	Generally low-cost generic	Higher branded or multisource product economics
PSVT role	Established acute treatment	Not a standard substitute
Patent exposure	Mature generic product	Product-specific patents and regulatory history
Commercial position	Commodity hospital injectable	Differentiated diagnostic product

Regadenoson does not eliminate adenosine demand because it is not a direct substitute for acute PSVT conversion. It can reduce adenosine use in nuclear stress testing, particularly where workflow simplicity and patient tolerance matter.

What generic entry risks exist for adenosine?

The generic entry risk is already realized. Adenosine is a multisource product, and additional suppliers can enter if they obtain FDA approval and secure sterile manufacturing capacity.

The risks for incumbent suppliers include:

• Price erosion from new ANDA approvals.
• Contract loss to group purchasing organizations.
• Hospital substitution among syringe, vial, and bag formats.
• Margin compression from raw-material and manufacturing-cost increases.
• Supply interruptions that trigger temporary share gains but invite accelerated competitor entry.
• Product discontinuation if volumes do not support quality and compliance costs.

For new entrants, the principal challenge is not patent freedom to operate. It is achieving adequate scale in sterile injectable production while maintaining acceptable margins.

Which companies are challenging adenosine’s market position?

The competitive threat comes from both generic manufacturers and alternative diagnostic agents.

Generic manufacturers

Generic injectable companies compete on:

• Bid price.
• Contract coverage.
• Backorder performance.
• Product availability.
• Packaging.
• Manufacturing reliability.
• Distributor relationships.

Supplier concentration can change rapidly following facility inspections, recalls, or acquisitions.

Therapeutic substitutes

For PSVT, alternatives include vagal maneuvers, synchronized cardioversion, beta blockers, calcium-channel blockers, and other antiarrhythmic approaches. These alternatives are clinically dependent on patient stability, rhythm characteristics, contraindications, and institutional protocols.

For cardiac stress testing, regadenoson is the leading pharmacologic substitute. Dipyridamole and dobutamine may also be used in selected settings, although their clinical profiles and workflows differ.[5]

What is the financial trajectory for adenosine?

Adenosine’s financial trajectory is flat to modestly declining in mature markets, with volume stability offset by price erosion. Revenue growth is more plausible in emerging markets than in the United States or Western Europe.

Public manufacturers generally do not disclose adenosine revenue as a standalone product line. It is usually included within broader hospital injectables, generic pharmaceuticals, or cardiovascular portfolios. As a result, precise drug-level revenue, gross margin, and market-share figures are not publicly verifiable from company reports.

Financial profile

Financial variable	Expected direction
U.S. unit volume	Stable to modest decline
U.S. net price	Downward pressure
Hospital stress-testing demand	Stable, with substitution toward regadenoson
PSVT demand	Stable and clinically recurring
Emerging-market volume	Potential growth
Gross margin	Low to moderate, depending on manufacturing scale
Revenue predictability	Moderate, with shortage-driven volatility
Patent-driven pricing power	Minimal
M&A value	Based on portfolio fit and supply capacity, not adenosine alone

Adenosine can still generate attractive strategic value when bundled with other hospital injectables. A manufacturer with excess sterile-fill capacity may use the product to improve plant utilization. A distributor may value it as an essential emergency-care SKU. A standalone acquisition thesis based only on adenosine revenue would be weak because the product lacks exclusivity and has limited pricing power.

What licensing deals affect adenosine?

No major current licensing transaction is required for generic adenosine injection because the molecule is off patent and widely available. Commercial agreements are more likely to involve:

• Contract manufacturing.
• Regional distribution.
• Hospital purchasing contracts.
• Private-label supply.
• Syringe or container technology.
• Imaging-agent collaborations.
• Portfolio acquisitions containing adenosine with other injectables.

The economically important agreements are supply and distribution contracts, not molecule-level licenses. A company seeking market entry would likely prioritize a compliant sterile manufacturing partner and hospital-channel access over a patent license.

What patent litigation affects adenosine?

Adenosine has low current litigation exposure relative to patented cardiovascular drugs, biologics, and proprietary drug-device combinations. Litigation risk would more likely arise from:

• A new proprietary formulation.
• A prefilled delivery device.
• A manufacturing-process patent.
• Trade-secret disputes involving sterile production.
• Product liability or quality claims.
• Contract disputes over supply or shortage allocation.

There is no apparent basis for treating standard adenosine injection as an active, high-value patent litigation market. The legal risk profile is primarily regulatory and commercial.

What geographic markets offer growth?

The United States is a mature market with strong generic penetration and limited pricing expansion. Western Europe has similar characteristics, although procurement structures and reimbursement systems differ by country.

Higher unit growth may occur in:

• China.
• India.
• Southeast Asia.
• Latin America.
• Middle Eastern markets expanding cardiac-care infrastructure.

Growth in these regions depends on hospital investment, nuclear cardiology capacity, electrophysiology adoption, local registration requirements, and the availability of reliable injectable manufacturing. Price levels are generally lower than in high-income markets, so volume expansion does not necessarily produce proportional revenue growth.

How strong is the adenosine patent estate?

The adenosine patent estate is weak for standard injectable products and stronger only for genuinely differentiated delivery or formulation technologies.

Patent-strength factor	Assessment
Composition-of-matter protection	Very weak or expired
Core method-of-use protection	Weak or expired
Standard injection formulation	Weak
Device-enabled delivery	Potentially moderate
Proprietary stress-testing workflow	Potentially moderate, dependent on claim scope
Manufacturing process	Narrow and implementation-specific
Ability to delay generic entry	Low
Freedom-to-operate risk for standard injection	Generally low, subject to product-specific review

The commercial value of adenosine lies in supply execution, not exclusivity.

What generic launch scenarios are likely?

Three scenarios define the market:

Base case: stable multisource supply

Several manufacturers remain active, hospital demand stays stable, and prices decline gradually. Adenosine remains a low-growth, dependable hospital injectable.

Downside case: excess competition and manufacturing exits

Additional suppliers enter, prices fall, and one or more manufacturers withdraw because margins no longer support sterile production. Shortages may emerge despite nominally adequate market capacity.

Upside case: differentiated presentation

A supplier launches a ready-to-use syringe, improved packaging, or a workflow solution that wins hospital contracts. Revenue gains come from share and operational value rather than molecule-level pricing power.

Key Takeaways

• Adenosine is a mature generic injectable with no meaningful remaining composition-of-matter exclusivity.
• Its main approved uses are PSVT conversion and pharmacologic myocardial perfusion stress testing.
• Regadenoson is the principal substitute in cardiac stress testing but does not replace adenosine for PSVT.
• U.S. revenue is likely stable to modestly declining because generic pricing offsets recurring clinical demand.
• Public companies generally do not report adenosine revenue separately.
• The main barriers to entry are sterile manufacturing, FDA compliance, distribution, and hospital contracting.
• Patent litigation and Paragraph IV challenges are unlikely to drive the current market.
• The best commercial opportunities involve supply reliability, private-label manufacturing, prefilled syringes, and growth markets outside the United States.
• Adenosine has limited standalone strategic value but can contribute to a broader hospital-injectables portfolio.

FAQs

Is adenosine still commercially profitable for generic manufacturers?

Yes, but profitability depends on manufacturing scale, contract access, and supply reliability. The drug has limited pricing power and is unlikely to support premium margins as a standalone product.

Can a new company patent a new adenosine product?

A company may patent a novel formulation, delivery device, manufacturing process, or combination product if the claims satisfy patentability requirements. The basic adenosine molecule is not a realistic source of new composition-of-matter exclusivity.

Does regadenoson replace adenosine in emergency cardiac care?

No. Regadenoson is primarily a pharmacologic stress-testing agent. Adenosine remains an established acute treatment for selected PSVT cases.

Why do hospitals experience adenosine shortages despite generic competition?

Sterile injectable production has concentrated manufacturing capacity and high compliance costs. A plant interruption, recall, raw-material constraint, or manufacturer exit can reduce supply even when several approved suppliers exist.

Is adenosine a suitable target for pharmaceutical licensing?

Adenosine alone is generally a weak licensing target. It may be attractive as part of a hospital-injectables portfolio, a regional supply agreement, or a differentiated ready-to-use delivery platform.

References

1. U.S. Food and Drug Administration. (2023). Adenosine injection prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. American Society of Nuclear Cardiology. (2016). ASNC imaging guidelines for single-photon emission computed tomography myocardial perfusion imaging. Journal of Nuclear Cardiology.